Labedipinedilol-A: A vanilloid-based α/β-adrenoceptor blocker with calcium entry blocking and long-acting antihypertensive properties

Drug Development Research

Volumn 49, Issue 2, 2000, Pages 94-108

  Liang, Jhy Chong ^a   Yeh, Jwu Lai ^a   Chiang, Lien Chai ^a   Yang, Yu Chiao ^a   Sheu, Sheng Hsiung ^a   Lai, Wen Ter ^a   Chen, Ing Jun ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

adrenoceptor blockade; 1,4 dihydropyridines; Calcium channel blockade; Vanilloid based

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; LABEDIPINEDILOL A; NIFEDIPINE; UNCLASSIFIED DRUG;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; GUINEA PIG; HEART RATE; HYPERTENSION; NONHUMAN; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 0033911860     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(200002)49:2<94::AID-DDR3>3.0.CO;2-V     Document Type: Article

References (35)

1. Asano M, Uchida W, Shibasaki K, Terai M, Inagaki O, Takenaka T, Matsumuto Y, Fujikura T. 1990. Pharmacological profiles of YM-16151-1 and optical isomers: a novel calcium entry blocking and selective beta-1 adrenoceptor blocking agent. J Pharmacol Exp Ther 296:204-211.
2. Baird JR, Linnell J. 1972. The assessment of β-adrenoceptor blocking potency and cardioselectivity in vitro and in vivo. J Pharm Pharmacol 24:880-885.
3. Bühler FR. 1997. Cardiovascular care with the new T-type calcium channel antagonist: possible role of attendant sympathetic nervous system inhibition. J Hypertens 15:S3-7.
4. Chang PC, van Brummelen P. Verineij R 1985. Acute vasodilator action of pindolol in humans. Hypertension 7:146-150.
5. Chen IJ, Lion SJ, Lion SS, Lin CN. 1993. Xanthonolol: a calcium channel and β-adrenoceptor blocker with vasodilating properties. Gen Pharmacol 24:1425-1433.
6. Chen IJ, Yeh JL, Lo YC, Sheu SH, Lin YT, 1996. Capsinolol: the first β-adrenoceptor blocker with an associated calcitonin gene-related peptide releasing activity in the heart. Br J Pharmacol 119:7-14.
7. 2-agonist and calcium mobilization inhibition associated vasorelaxant activities. Drug Dev Res 40:239-245.
8. Coburn RF, Baron CB. 1990. Coupling mechanisms in airway smooth muscle. Am J Rhysiol 258:L119-L133.
9. Doggrell SA, Brown L. 1998. Rat model of hypertension, cardiac hypertrophy and failure. Cardiovasc Res 39:89-105.
10. Frishman W, Silverman R, Strom J, Elkayam U, Sonnenblick E. 1979. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 4. Adverse effects. Choosing a β-adrenoceptor blocker. Ann Heart J 98:256-262.
11. 2-adrenoceptor agonist associated vasorelaxant activities. J Cardiovasc Pharmacol 34:10-20.
12. 2-agonist activity. Drug Dev Res 47:77-89.
13. Karaki H, Weiss GB. 1984. Calcium channels in smooth muscle. Gastroeuterology 87:960-970.
14. 1 -adrenoceptor antagonist. J Cardiovasc Pharmacol 28:149-157.
15. Meisheri KD, Sage GP, Cipkus-Dubray LA. 1990. Factors affecting rabbit mesenteric artery smooth muscle sensitivity to calcium antagonists. J Pharmacol Exp Ther 252:1167-1174.
16. Nobuhiro Y, Masahiko N, Kazumi O, Kazuhiro M, Toshio G. 1999. Pharmacologic characterization of FR172516: a new combined calcium channel-blocking and β-adrenoceptor-blocking agent J Cardiovasc Pharmacol 33:587-594.
17. Olivari MY, Batrorelli C, Polese A, Fiorentini C, Moruzzi P, Guazzi MD. 1979. Treatment of hypertension with nifedipine, a calcium antagonist agent. Circulation 59:1056-1062.
18. Ruffolo RR Jr, Boyle DA, Broobs DP. 1992. Carvedilol: a novel cardiovascular drug with multiple actions. Cardiovasc Drug Rev 10:127-157.
19. Ruffolo RR Jr, Feuserstein GZ, Ohlstein EH. 1998. Recent observation with β-adrenoceptor blockade. Am J Hypertens 11:9S-14S.
20. Satoh Y, Ichihashi M, Okumura K. 1991. Studies on nilvadipine. I. Synthesis and structure-activity relationships of 1,4-dihydropyridines containing novel substituents at the 2-position. Chem Pharm Bull 39:3189-3201.
21. Scarborough NL. Carrier GO. 1984. Nifedipine and alpha-adrenoceptors in rat aorta. I. Role of extracellular calcium in alpha-1 and alpha-2 adrenoceptor-mediated contraction. J Pharmacol Exp Ther 231:597-602.
22. Scatchard G. 1949. The attraction of protein for small molecules and ions. Ann NY Acad Sci 51:660-672.
23. Sheu MM, Wu BN, Ho WC;, Hong SJ, Chen SJ, Lin YT, Chen IJ. 1997. Vanidilol: a vanilloid-type vasorelaxant and ocular hypotensive beta-adrenoceptor blocker with partial beta-2 agonist activity. Pharmacology 54:211-224.
24. Shibasaki K, Arai Y, Uchida, W, Okazaki T, Asano M, Takenaka T. 1997a. Antianginal effects of YM 430, a novel calcium entry-blocking and β-adrenoceptor-blocking agent in several experimental angina models. Gen Pharmacol 29:545-550.
25. Shibasaki K, Takizawa K, Uchda W, Takenaka T. 1997b. Hypotensive effects of YM430, a 1,4-dihydropyridine derivative, in spontaneously hypertensive rats and renal hypertensive dogs. Jpn J Pharmacol 73:113-124.
26. Somlyo AP, Himpens B. 1989. Cell calcium and its regulation in smooth muscle. FASEB J 3:2266-2267.
27. Tham TC, Guy S, McDermott BJ, Shanks RG, Riddell JG. 1995. The dose dependency of the alpha-and beta-adrenoceptor antagonist activity of carvedilol on man. Br J Clin Pharmaco 40:19-23.
28. Uchida W, Shibasaki K, Matsuda Y, Asano M, Takenaka T. 1993. Cardiovascular effects of YM-16151-4: a novel calcium entry blocking and selective beta 1-adrenoceptor blocking agent in rats and dogs. J Cardiovasc Pharm 22:247-252.
29. 1-adrenoceptor antagonist derived from vanillin. Biochem Pharmacol 48:10-19.
30. Wu BN, Yang CR, Yang JM, Chen IJ. 1994b. A new β-adrenoceptor blocking agent derived from dehydrozingerone. Gen Pharmacol 25:651-659.
31. Wu BN, Hong SJ, Sheu MM, Chen IJ, Liu SX, Chiou GC. 1995. Vaninolol: a novel compound for the treatment of glaucoma and ischemic retinopathy. J Ocul Pharmacol Ther 11:21.3-230.
32. Wu BN, Ho WC, Chiang LC, Chen IJ. 1996. Zingeronolol: a newly developed β-adrenergic blocking agent derived from zingerone, a pungent principle of ginger. Asia Pac J Pharmacol 11:5-12.
33. 2-agonist activity derived form ferulic acid, an active component of ligusticum wallicii franch. J Cardiovasc Pharm 31:750-757.
34. Yen JL, Lo YC, Wang Y, Chen IJ. 1993. Cardiovascular interactions of nonivamide, glyceryl nonivamide, capsaicin analogues, and substance P antagonist in rats. Brain Res Bull 30:641-648.
35. Yeh JL, Liou SF, Liang JC, Huang YC, Chiang LC, Wu JR, Lin YT, Chen IJ. 2000. Vanidipinedilol: a vanilloid-based β-adrenoceptor blocker displaying calcium entry blocking and vasorelaxant activities. J Cardiovasc Pharmacol 35:51-63.